Tecovirimat is safe but ineffective as treatment for clade II mpox
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...
Technology Networks2d
Tecovirimat Is Safe but Ineffective as a Treatment for Mpox
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...
Pharmabiz9h
NIH-sponsored trial data shows tecovirimat is safe but ineffective as treatment for clade II mpox
Bethesda, Maryland Saturday, March 15, 2025, 10:00 Hrs [IST] ...
Mirage News2d
Tecovirimat Safe But Ineffective for Clade II Mpox
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...
ACTG Presents Data from Mpox Study STOMP at CROI
ACTG, a global clinical trials network focused on HIV and other infectious diseases, recently presented data demonstrating ...
NIH Trial Finds Tecovirimat Ineffective As Monotherapy For Mpox
A NIH-led trial found tecovirimat ineffective in reducing mpox lesion healing time or pain relief. The study was halted in 2024, with findings presented at CROI 2025.
Sierra Sun Times2d
NIH Reports Tecovirimat is Safe But Ineffective as Treatment for Clade II Mpox
NIH-sponsored trial data offers further evidence to help inform mpox treatment decisions.
Medical Xpress3d
Tecovirimat is safe but ineffective as treatment for clade II mpox
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international ...
NIH: Siga’s tecovirimat safe, but ineffective as treatment for Clade II Mpox
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve ...
News Medical3d
Tecovirimat monotherapy found ineffective for treating clade II mpox in NIH-sponsored trial
NIAID The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international ...